Application of a Drug-Induced Apoptosis Assay to Identify Treatment Strategies in Recurrent or Metastatic Breast Cancer

被引:11
作者
Bosserman, Linda [1 ]
Rogers, Karl [2 ]
Willis, Carl [2 ]
Davidson, Dirk [3 ]
Whitworth, Pat [4 ]
Karimi, Misagh [1 ]
Upadhyaya, Gargi [1 ]
Rutledge, James [5 ]
Hallquist, Allan [6 ]
Perree, Mathieu [6 ]
Presant, Cary A. [1 ,6 ]
机构
[1] US Oncol, Wilshire Oncol Med Grp, La Verne, CA USA
[2] Nashville Oncol Associates, Nashville, TN USA
[3] Tennessee Plateau Oncol, Crossville, TN USA
[4] Nashville Breast Ctr, Nashville, TN USA
[5] Data Vis, Dayton, OH USA
[6] DiaTech Oncol, Montreal, PQ, Canada
来源
PLOS ONE | 2015年 / 10卷 / 05期
关键词
MICROCULTURE KINETIC ASSAY; MICK ASSAY; IN-VITRO;
D O I
10.1371/journal.pone.0122609
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background A drug-induced apoptosis assay has been developed to determine which chemotherapy drugs or regimens can produce higher cell killing in vitro. This study was done to determine if this assay could be performed in patients with recurrent or metastatic breast cancer patients, to characterize the patterns of drug-induced apoptosis, and to evaluate the clinical utility of the assay. A secondary goal was to correlate assay use with clinical outcomes. Methods In a prospective, non-blinded, multi institutional controlled trial, 30 evaluable patients with recurrent or metastatic breast cancer who were treated with chemotherapy had tumor samples submitted for the MiCK drug-induced apoptosis assay. After receiving results within 72 hours after biopsy, physicians could use the test to determine therapy (users), or elect to not use the test (non-users). Results The assay was able to characterize drug-induced apoptosis in tumor specimens from breast cancer patients and identified which drugs or combinations gave highest levels of apoptosis. Patterns of drug activity were also analyzed in triple negative breast cancer. Different drugs from a single class of agents often produced significantly different amounts of apoptosis. Physician frequently (73%) used the assay to help select chemotherapy treatments in patients, Patients whose physicians were users had a higher response (CR+PR) rate compared to non-users (38.1% vs 0%, p = 0.04) and a higher disease control (CR+PR+Stable) rate (81% vs 25%, p<0.01). Time to relapse was longer in users 7.4 mo compared to non-users 2.2 mo (p<0.01). Conclusions The MiCK assay can be performed in breast cancer specimens, and results are often used by physicians in breast cancer patients with recurrent or metastatic disease. These results from a good laboratory phase II study can be the basis for a future larger prospective multi-center study to more definitively establish the value of the assay.
引用
收藏
页数:14
相关论文
共 18 条
[1]   Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents [J].
Andre, F. ;
Zielinski, C. C. .
ANNALS OF ONCOLOGY, 2012, 23 :46-51
[2]   Endometrial carcinoma in vitro chemosensitivity testing of single and combination chemotherapy regimens using the novel microculture kinetic apoptosis assay: implications for endometrial cancer treatment [J].
Ballard, Karen S. ;
Homesley, Howard D. ;
Hodson, Charles ;
Presant, Cary A. ;
Rutledge, James ;
Hallquist, Allan ;
Perree, Mathieu .
JOURNAL OF GYNECOLOGIC ONCOLOGY, 2010, 21 (01) :45-49
[3]   The Microculture-Kinetic (MiCK) Assay: The Role of a Drug-Induced Apoptosis Assay in Drug Development and Clinical Care [J].
Bosserman, Linda ;
Prendergast, Franklyn ;
Herbst, Roy ;
Fleisher, Martin ;
Salom, Emery ;
Strickland, Steven ;
Raptis, Anastasios ;
Hallquist, Allan ;
Perree, Mathieu ;
Rajurkar, Swapnil ;
Karimi, Misagh ;
Rogers, Karl ;
Davidson, Dirk ;
Willis, Carl ;
Penalver, Manuel ;
Homesley, Howard ;
Burrell, Matthew ;
Garrett, Audrey ;
Rutledge, James ;
Chernick, Michael ;
Presant, Cary A. .
CANCER RESEARCH, 2012, 72 (16) :3901-3905
[4]   Correlation of drug-induced apoptosis assay results with oncologist treatment decisions and patient response and survival [J].
Bosserman, Linda D. ;
Rajurkar, Swapnil P. ;
Rogers, Karl ;
Davidson, Dirk C. ;
Chernick, Michael ;
Hallquist, Allan ;
Malouf, Debbee ;
Presant, Cary A. .
CANCER, 2012, 118 (19) :4877-4883
[5]   American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Chemotherapy Sensitivity and Resistance Assays [J].
Burstein, Harold J. ;
Mangu, Pamela B. ;
Somerfield, Mark R. ;
Schrag, Deborah ;
Samson, David ;
Holt, Lawrence ;
Zelman, Debra ;
Ajani, Jaffer A. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (24) :3328-3330
[6]  
COX DR, 1972, J R STAT SOC B, V34, P187
[7]  
Greenwood P., 1996, A Guide to Chi-Squared Testing, DOI DOI 10.2307/1271520
[8]   Triple-Negative Breast Cancer: An Unmet Medical Need [J].
Hudis, Clifford A. ;
Gianni, Luca .
ONCOLOGIST, 2011, 16 :1-11
[9]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481
[10]  
Kravtsov VD, 1998, BLOOD, V92, P968